ReviewAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2024
SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art.
Review in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- SGLT2 Inhibitors in Cardio-Oncology: A Systematic Review and Meta-Analysis.JACC. Advances · 2026Article
- Article
- Sodium-glucose cotransporter-2 inhibitors and sepsis: a story with two tails or with one tail?Inflammopharmacology · 2026Review
- Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus.World journal of diabetes · 2025Article
- Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases.Pharmacological reviews · 2025Review
- SGLT2 Inhibitors in Patients with Urogenital Malformations and Urinary Diversions: Risks, Benefits, and Clinical Considerations.Medicina (Kaunas, Lithuania) · 2025Review
- Article
- Impact of Angiotensin Receptor-Neprilysin Inhibitors on Patients With Acute Heart Failure Syndrome.Cureus · 2025Article
- A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review.Frontiers in endocrinology · 2025Review
- Article
- Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety.Frontiers in medicine · 2025Review
- Comment on "SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect".American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Article
- Inflammatory and lipotoxicity mechanisms in obesity related CKD.Frontiers in nephrology · 2025Review
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) is associated with a heightened risk of cardiovascular and renal complications. While glycemic control remains essential, newer therapeutic options, such as SGLT2 inhibitors, offer additional benefits beyond glucose reduction. This review delves into the mechanisms underlying the cardio-renal protective effects of SGLT2 inhibitors. By inducing relative hypoglycemia, these agents promote ketogenesis, optimize myocardial energy metabolism, and reduce lipotoxicity. Additionally, SGLT2 inhibitors exert renoprotective actions by enhancing renal perfusion, attenuating inflammation, and improving iron metabolism. These pleiotropic effects, including modulation of blood pressure, reduction of uric acid, and improved endothelial function, collectively contribute to the cardiovascular and renal benefits observed with SGLT2 inhibitor therapy. This review will provide clinicians with essential knowledge, understanding, and a clear recollection of this pharmacological group's mechanism of action.
Indexed as
Identifiers
39179723What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.